ASH 2021 | Outcomes of reduced intensity alloSCT in patients with accelerated-phase myelofibrosis
Accelerated-phase (AP) myelofibrosis (MF) is defined by circulating blasts between 10-19% and is associated with poor outcomes. Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses the results of a study investigating the outcomes of patients with AP MF undergoing reduced intensity allogeneic stem cell transplantation (alloSCT) compared to patients with 0%, 1-4% and 5-9% circulating blasts. Overall, reduced intensity alloSCT was associated with significantly improved survival and non-relapse mortality (NRM) in AP MF in comparison to other blast groups. However, incidence of relapse appeared to be higher in patients with AP MF. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Transcript (edited for clarity)
I’m happy to present an oral abstract on reduced intensity hematopoietic stem cell transplantation in accelerated phase myelofibrosis. Allogeneic stem cell transplantation still is the only curative treatment option for myelofibrosis, but the role in accelerated phase cell blast circulating blasts from 10% to 19% at time of transplantation is completely unknown. So there are no reports on the role of transplant on curative therapy in that setting, and that’s why we underwent a multicenter retrospective study evaluating 35 patients with accelerated phase myelofibrosis and found excellent outcome, overall survival, non-relapse mortality, relapse-free survival in comparison to patients without accelerated phase, which we call chronic phase with 0% to 10% circulating blasts at time of transplantation...
I’m happy to present an oral abstract on reduced intensity hematopoietic stem cell transplantation in accelerated phase myelofibrosis. Allogeneic stem cell transplantation still is the only curative treatment option for myelofibrosis, but the role in accelerated phase cell blast circulating blasts from 10% to 19% at time of transplantation is completely unknown. So there are no reports on the role of transplant on curative therapy in that setting, and that’s why we underwent a multicenter retrospective study evaluating 35 patients with accelerated phase myelofibrosis and found excellent outcome, overall survival, non-relapse mortality, relapse-free survival in comparison to patients without accelerated phase, which we call chronic phase with 0% to 10% circulating blasts at time of transplantation.
The only thing that we found was that the risk for relapse was increased in that group compared to chronic phase myelofibrosis, and that’s why we underline that the accelerated phase group has excellent outcome but needs to be screened for relapse risk, and that’s why we encourage everyone to screen patients with accelerated phase, whether they are capable of undergoing transplant, and then we screen them for relapse risk afterwards.
Read more...
